Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Santilli, B. Rocca, R. Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, Elisabetta Ferrante, G. Ciabattoni, G. Davı̀, C. Patrono (2009)
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".Journal of the American College of Cardiology, 53 8
F. Chan, N. Abraham, J. Scheiman, L. Laine (2008)
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet AgentsThe American Journal of Gastroenterology, 103
(2012)
Assessment report for Non-Steroidal Anti-Inflammatory Drugs ( NSAIDs ) and cardiovascular risk
P. McGettigan, D. Henry (2011)
Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational StudiesPLoS Medicine, 8
H. Bueno, A. Bardají, P. Patrignani, E. Martín-Merino, L. García-Rodríguez (2010)
Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome.The American journal of cardiology, 105 8
C. Rolf, B. Engstrom, C. Beauchard, L.-D. Jacobs, A. Liboux (1999)
Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy.Rheumatology, 38 6
Information for healthcare professionals: comcomitant use of ibuprofen and aspirin
S. Trelle, S. Reichenbach, Simon Wandel, Pius Hildebrand, B. Tschannen, Peter Villiger, M. Egger, P. Jüni (2011)
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysisThe BMJ, 342
S. Cronberg, E. Wallmark, I. Söderberg (2009)
Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans.Scandinavian journal of haematology, 33 2
H. Bueno, A. Bardají, P. Patrignani, E. Martín-Merino, A. García-Rodríguez (2010)
USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND TYPE-SPECIFIC RISK OF ACUTE CORONARY SYNDROMEJournal of the American College of Cardiology, 55
CarloPatrono, ColinBaigent (2014)
Nonsteroidal Anti-Inflammatory Drugs and the Heart
Judy Cheng (2006)
Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular EventsAnnals of Pharmacotherapy, 40
C. Baigent, N. Bhala, J. Emberson, A. Merhi, S. Abramson, N. Arber, J. Baron, C. Bombardier, C. Cannon, M. Farkouh, G. FitzGerald, P. Goss, H. Halls, E. Hawk, C. Hawkey, C. Hennekens, M. Hochberg, L. Holland, P. Kearney, L. Laine, Á. Lanas, P. Lance, A. Laupacis, J. Oates, C. Patrono, T. Schnitzer, S. Solomon, P. Tugwell, K. Wilson, J. Wittes, O. Adelowo, P. Aisen, A. Al-Quorain, R. Altman, G. Bakris, Helmut Baumgartner, C. Bresee, M. Carducci, D. Chang, C. Chou, D. Clegg, M. Cudkowicz, L. Doody, Y. Miedany, C. Falandry, J. Farley, L. Ford, M. García-Losa, M. González-Ortiz, M. Haghighi, M. Hala, T. Iwama, Z. Jajić, D. Kerr, H. Kim, C.-H. Köhne, B. Koo, B. Martin, C. Meinert, N. Muller, G. Myklebust, D. Neustadt, R. Omdal, S. Ozgoçmen, A. Papas, P. Patrignani, F. Pelliccia, V. Roy, I. Schlegelmilch, A. Umar, O. Wahlstrom, F. Wollheim, S. Yocum, Xin Zhang, E. Hall, P. McGettigan, R. Midgley, R. Moore, R. Philipson, S. Curtis, A. Reicin, J. Bond, A. Moore, M. Essex, J. Fabule, B. Morrison, L. Tive, K. Davies, F. Yau (2013)
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsLancet, 382
AA Bavry, A Khaliq, Y Gong, EM Handberg, RM Cooper-Dehoff, CJ Pepine (2011)
Harmful effects of NSAIDs among patients with hypertension and coronary artery diseaseAm J Med., 124
P. McGettigan, D. Henry (2006)
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.JAMA, 296 13
I. Reilly, G. FitzGerald (1987)
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.Blood, 69 1
Clinical Pharmacology and Cardiovascular Safety of Naproxen
L. Timmers, J. Sluijter, C. Verlaan, P. Steendijk, M. Cramer, M. Emons, C. Strijder, P. Gründeman, S. Sze, Lin Hua, J. Piek, C. Borst, G. Pasterkamp, D. Kleijn (2007)
Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the PigCirculation, 115
I. Tegeder, G. Geisslinger (2006)
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Naunyn-Schmiedeberg's Archives of Pharmacology, 373
B. Costa, S. Reichenbach, N. Keller, L. Nartey, Simon Wandel, P. Jüni, S. Trelle (2017)
Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysisThe Lancet, 390
C. Patrono (1994)
Aspirin as an antiplatelet drug.The New England journal of medicine, 330 18
N. Kirkby, M. Lundberg, L. Harrington, P. Leadbeater, G. Milne, Claire Potter, M. Al’Yamani, O. Adeyemi, T. Warner, J. Mitchell (2012)
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular systemProceedings of the National Academy of Sciences, 109
F. Catella-Lawson, L. Crofford (2001)
Cyclooxygenase inhibition and thrombogenicity.The American journal of medicine, 110 Suppl 3A
H. Yokoyama, Takehiro Yaguchi, Yuji Suzuki, K. Tokuoka, Masayuki Watanabe, Y. Kitagawa, Yasuhiko Yamada (2012)
Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.Biological & pharmaceutical bulletin, 35 12
(2016)
and Drug Administration
(2014)
Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee briefing document
K. Schrör, S. Nitschmann (2017)
[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].Der Internist, 58 8
S. Rich (2001)
The coxibs, selective inhibitors of cyclooxygenase-2.The New England journal of medicine, 345 23
R. Bresalier, R. Sandler, H. Quan, J. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, Á. Lanas, M. Konstam, J. Baron (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.The New England journal of medicine, 352 11
C. Wilcox, B. Cryer, G. Triadafilopoulos (2005)
Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs.The Journal of rheumatology, 32 11
E. Ott, N. Nussmeier, P. Duke, R. Feneck, R. Alston, M. Snabes, R. Hubbard, P. Hsu, L. Saidman, L. Saidman, D. Mangano (2003)
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.The Journal of thoracic and cardiovascular surgery, 125 6
-releases/Last-5-years/scot-study-quells-concerns-aboutnsaid-safety
T. Aw, S. Haas, D. Liew, H. Krum (2005)
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood PressureAcc Current Journal Review, 14
S. Furey, R. Vargas, F. Mcmahon (1993)
Renovascular Effects of Nonprescription Ibuprofen in Elderly Hypertensive Patients With Mild Renal ImpairmentPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 13
Deepak Bhatt, J. Scheiman, N. Abraham, E. Antman, Francis Chan, C. Furberg, David Johnson, K. Mahaffey, E. Quigley, R. Harrington, E. Bates, C. Bridges, M. Eisenberg, V. Ferrari, M. Hlatky, S. Kaul, J. Lindner, D. Moliterno, D. Mukherjee, R. Schofield, R. Rosenson, J. Stein, H. Weitz, D. Wesley (2008)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Journal of the American College of Cardiology, 52 18
(2010)
Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings)
J. Polónia, I. Boaventura, G. Gama, I. Camões, Fátima Bernardo, Paulo Andrade, J. Nunes, F. Brandão, M. Cerqueira‐Gomes (1995)
Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patientsJournal of Hypertension, 13
(2011)
The pharmacological basis of therapeutics anti-inflammatory, antipyretic, and analgesic agents; Pharmacotherapy of Gout
J. Pope, Jennifer Anderson, D. Felson (1993)
A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure.Archives of internal medicine, 153 4
R. Moore, S. Derry, H. McQuay (2007)
Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular riskBMC Musculoskeletal Disorders, 8
Xin Li, M. Cooper (2012)
Measurement of drug lipophilicity and pKa using acoustics.Analytical chemistry, 84 6
K. Brune, B. Renner, B. Hinz (2010)
Using pharmacokinetic principles to optimize pain therapyNature Reviews Rheumatology, 6
Marta Capone, S. Tacconelli, M. Sciulli, M. Grana, E. Ricciotti, P. Minuz, P. Gregorio, Gabriele Merciaro, C. Patrono, P. Patrignani (2004)
Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy SubjectsCirculation: Journal of the American Heart Association, 109
J. Baron, R. Sandler, R. Bresalier, Á. Lanas, D. Morton, R. Riddell, E. Iverson, D. DeMets (2008)
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trialThe Lancet, 372
Gurkirpal Singh (2000)
Gastrointestinal Complications of Prescription and Over-the-Counter Nonsteroidal Anti-inflammatory Drugs: A View from the ARAMIS DatabaseAmerican Journal of Therapeutics, 7
(2014)
J Thromb Haemost
E. Fosbøl, G. Gislason, S. Jacobsen, F. Folke, M. Hansen, T. Schramm, R. Sørensen, J. Rasmussen, S. Andersen, S. Abildstrom, J. Traerup, H. Poulsen, S. Rasmussen, L. Køber, C. Torp-Pedersen (2009)
Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti‐Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort StudyClinical Pharmacology & Therapeutics, 85
J. Curtis, H. Krumholz (2003)
Effect of ibuprofen on cardioprotective effect of aspirinThe Lancet, 361
B. DeArmond, C. Francisco, J. Lin, F. Huang, S. Halladay, R. Bartziek, K. Skare (1995)
Safety profile of over-the-counter naproxen sodium.Clinical therapeutics, 17 4
N. Moore, F. Salvo, Mai Duong, P. Blin, A. Pariente (2014)
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTCExpert Opinion on Drug Safety, 13
W. Smith, D. Dewitt, R. Garavito (2000)
Cyclooxygenases: structural, cellular, and molecular biology.Annual review of biochemistry, 69
J. Sowers, W. White, B. Pitt, A. Whelton, L. Simon, H. Ingen, J. Fort (2003)
OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitusAmerican Journal of Hypertension, 16
D. Klassen, T. Goodfriend, A. Schuna, D. Young, C. Peterson (1993)
Assessment of Blood Pressure During Treatment with Naproxen or Ibuprofen in Hypertensive Patients Treated with HydrochlorothiazideThe Journal of Clinical Pharmacology, 33
Ying Yu, J. Stubbe, Salam Ibrahim, Wenliang Song, Emer Symth, C. Funk, G. FitzGerald (2010)
Cyclooxygenase-2–Dependent Prostacyclin Formation and Blood Pressure Homeostasis: Targeted Exchange of Cyclooxygenase Isoforms in MiceCirculation Research, 106
Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community
RS Bresalier, RS Sandler, H Quan (2005)
APPROVe Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med., 352
K. Knights, A. Mangoni, J. Miners (2010)
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicityExpert Review of Clinical Pharmacology, 3
S. Maxwell, R. Payne, G. Murray, D. Webb (2006)
Selectivity of NSAIDs for COX-2 and cardiovascular outcome.British journal of clinical pharmacology, 62 2
A. Hata, R. Breyer (2004)
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation.Pharmacology & therapeutics, 103 2
Taeyeon Lee, N. Lu, D. Felson, Hyon Choi, D. Dalal, Yuqing Zhang, M. Dubreuil (2016)
Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study.Rheumatology, 55 6
P. Patrignani, S. Tacconelli, A. Bruno, C. Sostres, Á. Lanas (2011)
Managing the adverse effects of nonsteroidal anti-inflammatory drugsExpert Review of Clinical Pharmacology, 4
W. Kean, C. Lock, J. Rischke, R. Butt, W. Buchanan, H. Howard-Lock (1989)
Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets.Journal of pharmaceutical sciences, 78 4
NS Kirkby, MH Lundberg, LS Harrington (2012)
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular systemProc Natl Acad Sci U S A., 109
E. Antman, J. Bennett, A. Daugherty, C. Furberg, H. Roberts, K. Taubert (2007)
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.Circulation, 115 12
M. Gaffney (2016)
Statistical issues in the design, conduct and analysis of two large safety studiesClinical Trials, 13
(1995)
J Hypertens
T. Towheed, L. Maxwell, M. Judd, M. Catton, M. Hochberg, G. Wells (2006)
Acetaminophen for osteoarthritis.The Cochrane database of systematic reviews, 2
A. Malmberg, T. Yaksh (1992)
Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition.Science, 257 5074
Marta Capone, M. Sciulli, S. Tacconelli, M. Grana, E. Ricciotti, G. Renda, P. Gregorio, Gabriele Merciaro, P. Patrignani (2005)
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.Journal of the American College of Cardiology, 45 8
A. Rostom, P. Moayyedi, R. Hunt (2009)
Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risksAlimentary Pharmacology & Therapeutics, 29
M. Houston, M. Weir, James Gray, David Ginsberg, Caroline Szeto, Paul Kaihlenen, D. Sugimoto, Mark Runde, M. Lefkowitz (1995)
The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.Archives of internal medicine, 155 10
Marta Capone, S. Tacconelli, L. Francesco, A. Sacchetti, M. Sciulli, P. Patrignani (2007)
Pharmacodynamic of cyclooxygenase inhibitors in humans.Prostaglandins & other lipid mediators, 82 1-4
M. Farkouh, J. Greenberg, R. Jeger, K. Ramanathan, F. Verheugt, J. Chesebro, H. Kirshner, J. Hochman, C. Lay, S. Ruland, B. Mellein, P. Matchaba, V. Fuster, S. Abramson (2007)
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxibAnnals of the Rheumatic Diseases, 66
(2014)
Mechanistic basis for a cardiovascular hazard from NSAIDs
MC Hochberg, RD Altman, KT April (2012)
American College of Rheumatology American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care Res (Hoboken)., 64
B. Martin (2006)
Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)PLoS Clinical Trials, 1
M. Weir (2002)
Renal effects of nonselective NSAIDs and coxibs.Cleveland Clinic journal of medicine, 69 Suppl 1
P. Patrignani, S. Tacconelli, E. Piazuelo, L. Francesco, M. Dovizio, C. Sostres, Emanuela Marcantoni, P. Guillem-Llobat, P. Boccio, M. Zucchelli, C. Patrono, Á. Lanas (2014)
Reappraisal of the clinical pharmacology of low‐dose aspirin by comparing novel direct and traditional indirect biomarkers of drug actionJournal of Thrombosis and Haemostasis, 12
G Singh (2000)
Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database: arthritis, rheumatism, and aging medical information systemAm J Ther., 7
H. François, K. Athirakul, D. Howell, Rajesh Dash, L. Mao, Hyung-Suk Kim, H. Rockman, G. FitzGerald, B. Koller, T. Coffman (2005)
Prostacyclin protects against elevated blood pressure and cardiac fibrosis.Cell metabolism, 2 3
J. Gurwitz, D. Everitt, M. Monane, R. Glynn, I. Choodnovskiy, M. Beaudet, J. Avorn (1996)
The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.The journals of gerontology. Series A, Biological sciences and medical sciences, 51 2
Walter Kean, K. Rainsford, I. Kean (2008)
Management of chronic musculoskeletal pain in the Elderly: Opinions on oral medication useInflammopharmacology, 16
A. Morrison, D. Ramey, J. Adelsberg, D. Watson (2007)
Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension*Current Medical Research and Opinion, 23
G. Renda, S. Tacconelli, Marta Capone, D. Sacchetta, F. Santarelli, M. Sciulli, M. Zimarino, M. Grana, E. D'amelio, M. Zurro, Thomas Price, C. Patrono, R. Caterina, P. Patrignani (2006)
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart diseaseClinical Pharmacology & Therapeutics, 80
M. Farkouh, H. Kirshner, R. Harrington, S. Ruland, F. Verheugt, T. Schnitzer, G. Burmester, E. Mysler, M. Hochberg, M. Doherty, E. Ehrsam, X. Gitton, G. Krammer, B. Mellein, A. Gimona, P. Matchaba, C. Hawkey, J. Chesebro (2004)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialThe Lancet, 364
A. Bruno, S. Tacconelli, P. Patrignani (2014)
Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.Basic & clinical pharmacology & toxicology, 114 1
A. Helin‐Salmivaara, A. Virtanen, R. Vesalainen, J. Grönroos, T. Klaukka, J. Idänpään-Heikkilä, R. Huupponen (2006)
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.European heart journal, 27 14
(2015)
of Health
M. Hochberg, R. Altman, K. April, M. Benkhalti, G. Guyatt, J. McGowan, T. Towheed, V. Welch, G. Wells, P. Tugwell (2012)
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 64
P. Rao, E. Knaus (2008)
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 11 2
T. Bowman, J. Gaziano, C. Kase, H. Sesso, T. Kurth (2006)
Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in menNeurology, 67
T. Grosser, Susanne Fries, G. FitzGerald (2005)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.The Journal of clinical investigation, 116 1
G. Gislason, J. Rasmussen, S. Abildstrom, T. Schramm, M. Hansen, E. Fosbøl, R. Sørensen, F. Folke, P. Buch, N. Gadsbøll, S. Rasmussen, H. Poulsen, L. Køber, M. Madsen, C. Torp-Pedersen (2009)
Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.Archives of internal medicine, 169 2
N. Nussmeier, A. Whelton, Mark Brown, R. Langford, A. Hoeft, J. Parlow, S. Boyce, K. Verburg (2005)
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.The New England journal of medicine, 352 11
R. Palmer, R. Weiss, R. Zusman, A. Haig, S. Flavin, B. Macdonald (2003)
Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.American journal of hypertension, 16 2
C. Patrono, P. Patrignani, L. Rodríguez (2001)
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.The Journal of clinical investigation, 108 1
K. Brune (2007)
Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerabilityCurrent Medical Research and Opinion, 23
Jason Boland (2011)
Articles of interest in other scholarly journalsBMJ Supportive & Palliative Care, 1
K. Brune, D. Furst (2007)
Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?Rheumatology, 46 6
T. Aw, S. Haas, D. Liew, H. Krum (2005)
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.Archives of internal medicine, 165 5
L. Rodríguez, S. Tacconelli, P. Patrignani (2008)
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population.Journal of the American College of Cardiology, 52 20
Paola Anzellotti, Marta Capone, A. Jeyam, S. Tacconelli, A. Bruno, P. Tontodonati, L. Francesco, L. Grossi, G. Renda, Gabriele Merciaro, P. Gregorio, Thomas Price, L. Rodríguez, P. Patrignani (2011)
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.Arthritis and rheumatism, 63 3
(2006)
Available at: http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/UCM161282.pdf. Accessed Feb
K. Knights, L. Winner, D. Elliot, K. Bowalgaha, J. Miners (2009)
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.British journal of clinical pharmacology, 68 3
L. Laine (2001)
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.Gastroenterology, 120 3
Jingjing Zhang, E. Ding, Yiqing Song (2006)
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.JAMA, 296 13
The voluntary withdrawal of Vioxx (rofecoxib) from the market in 2004, as well as the 2005 and 2014 US FDA Advisory Committee meetings about non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk, have raised questions surrounding the use of NSAIDs in at-risk populations. This paper discusses the cardiovascular safety profile of naproxen in the context of the NSAID class. The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2 selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs. The over-the-counter (OTC) use of naproxen is expected to pose minimal cardiovascular risk; however, the benefit–risk ratio and appropriate use should be considered at an individual patient level, particularly to assess underlying conditions that may increase the risk of events. Likewise, regulatory authorities should revisit label information periodically to ensure labeling reflects the current understanding of benefits and risks.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Nov 8, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.